Response to: Letter to the Editor with Regard to the Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands

Adv Ther. 2023 May;40(5):2545-2548. doi: 10.1007/s12325-023-02431-2. Epub 2023 Mar 9.
No abstract available

Keywords: Advanced hybrid closed-loop; Cost-effectiveness; Netherlands; Type 1 diabetes.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Blood Glucose
  • Blood Glucose Self-Monitoring
  • Cost-Benefit Analysis
  • Diabetes Mellitus, Type 1* / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Insulin Infusion Systems
  • Netherlands

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin